6-K – Report of foreign issuer [Rules 13a-16 and 15d-16]

On June 22, 2015 Aptose Biosciences reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming 10th Annual JMP Securities Life Sciences Conference on Wednesday, June 24th at 10:30 a.m. ET at the St. Regis New York (Filing, 6-K, Aptose Biosciences, JUN 22, 2015, View Source [SID:1234505790]). Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction, including the development of Aptose’s lead clinical agent, APTO-253, for acute myeloid leukemia (AML), high risk myelodysplastic syndromes (MDS) and other hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Aptose presentation will be accessible by visiting:

View Source

The audio webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com.